Clinical trial
Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan
NCT00258908 · Sanofi Pasteur, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00258908 |
|---|---|
| Title | Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan |
| Official title | Immunogenicity and Safety of ADACEL™ (TdcP Vaccine) as Fifth Dose in Children 6-8 Years of Age. |
| Lead sponsor | Sanofi Pasteur, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diphtheria, Tetanus, Pertussis |
| Intervention type | Biological |
| Interventions | Diphteria, tetanus, and Acellular Pertussis vaccine |
| Enrollment | 115 |
| Start date | Nov 1, 2005 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Nov 28, 2005 |
| Last update posted | Apr 14, 2016 |
| Countries | Taiwan |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: